mdrx-10q_20180930.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2018

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number 001-35547

 

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

 

Delaware

 

36-4392754

(State or Other Jurisdiction of

Incorporation or Organization)

 

(I.R.S. Employer

Identification No.)

222 Merchandise Mart, Suite 2024

Chicago, IL 60654

(Address of Principal Executive Offices, Zip Code)

(800) 334-8534

(Registrant's Telephone Number, Including Area Code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes        No   

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).      Yes        No   

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

  

Accelerated filer

 

 

 

 

 

Non-accelerated filer

 

  

 

Smaller reporting company

 

 

 

 

 

 

 

 

 

 

 

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.      

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).      Yes        No   

As of November 1, 2018, there were 174,714,207 shares of the registrant's $0.01 par value common stock outstanding.

 

 


ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

FORM 10-Q

For the Fiscal Quarter Ended September 30, 2018

TABLE OF CONTENTS

 

 

  

 

 

PAGE

PART I. FINANCIAL INFORMATION

 

3

Item 1.

 

Financial Statements (unaudited)

 

3

Item 2.

 

Management's Discussion and Analysis of Financial Condition and Results of Operations

 

41

Item 3.

 

Quantitative and Qualitative Disclosures About Market Risk

 

57

Item 4.

 

Controls and Procedures

 

57

PART II. OTHER INFORMATION

 

58

Item 1.

 

Legal Proceedings

 

58

Item 1A.

 

Risk Factors

 

58

Item 6.

 

Exhibits

 

58

SIGNATURES

 

59

 

2


PART I. FINANCIAL INFORMATION

Item 1.

Financial Statements 

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

CONSOLIDATED BALANCE SHEETS

(Unaudited)

 

(In thousands, except per share amounts)

 

September 30, 2018

 

 

December 31, 2017

 

ASSETS

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

111,775

 

 

$

155,839

 

Restricted cash

 

 

8,016

 

 

 

6,659

 

Accounts receivable, net of allowance of $61,926 and $37,735 as of

   September 30, 2018 and December 31, 2017, respectively

 

 

520,381

 

 

 

567,873

 

Contract assets

 

 

71,745

 

 

 

0

 

Prepaid expenses and other current assets

 

 

131,826

 

 

 

115,463

 

Total current assets

 

 

843,743

 

 

 

845,834

 

Fixed assets, net

 

 

160,225

 

 

 

165,603

 

Software development costs, net

 

 

239,359

 

 

 

222,189

 

Intangible assets, net

 

 

873,635

 

 

 

826,872

 

Goodwill

 

 

2,207,967

 

 

 

2,004,953

 

Deferred taxes, net

 

 

5,566

 

 

 

4,574

 

Contract assets - long-term

 

 

52,555

 

 

 

0

 

Other assets

 

 

135,030

 

 

 

148,849

 

Long-term assets attributable to discontinued operations

 

 

0

 

 

 

11,276

 

Total assets

 

$

4,518,080

 

 

$

4,230,150

 

 


3


ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

CONSOLIDATED BALANCE SHEETS (CONTINUED)

(Unaudited)

 

(In thousands, except per share amounts)

 

September 30, 2018

 

 

December 31, 2017

 

LIABILITIES AND STOCKHOLDERS' EQUITY

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

126,709

 

 

$

97,583

 

Accrued expenses

 

 

120,326

 

 

 

85,915

 

Accrued compensation and benefits

 

 

107,799

 

 

 

99,632

 

Deferred revenue

 

 

506,568

 

 

 

546,830

 

Current maturities of long-term debt

 

 

19,516

 

 

 

27,687

 

Current maturities of non-recourse long-term debt - Netsmart

 

 

4,257

 

 

 

2,755

 

Current maturities of capital lease obligations

 

 

9,190

 

 

 

7,865

 

Total current liabilities

 

 

894,365

 

 

 

868,267

 

Long-term debt

 

 

1,002,026

 

 

 

906,725

 

Non-recourse long-term debt - Netsmart

 

 

788,489

 

 

 

625,193

 

Long-term capital lease obligations

 

 

4,606

 

 

 

7,105

 

Deferred revenue

 

 

21,804

 

 

 

24,047

 

Deferred taxes, net

 

 

124,294

 

 

 

93,643

 

Other liabilities

 

 

95,575

 

 

 

92,205

 

Liabilities attributable to discontinued operations

 

 

2,261

 

 

 

21,358

 

Total liabilities

 

 

2,933,420

 

 

 

2,638,543

 

Redeemable convertible non-controlling interest - Netsmart

 

 

467,981

 

 

 

431,535

 

Commitments and contingencies

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

Preferred stock: $0.01 par value, 1,000 shares authorized,

   no shares issued and outstanding as of September 30, 2018 and December 31, 2017

 

 

0

 

 

 

0

 

Common stock: $0.01 par value, 349,000 shares authorized as of September 30, 2018

   and December 31, 2017; 270,506 and 174,707 shares issued and outstanding as of

   September 30, 2018, respectively; 269,335 and 180,832 shares issued and outstanding

   as of December 31, 2017, respectively

 

 

2,708

 

 

 

2,693

 

Treasury stock: at cost, 96,099 and 88,504 shares as of September 30, 2018 and

   December 31, 2017, respectively

 

 

(423,521

)

 

 

(322,735

)

Additional paid-in capital

 

 

1,765,103

 

 

 

1,781,059

 

Accumulated deficit

 

 

(251,363

)

 

 

(338,150

)

Accumulated other comprehensive loss

 

 

(5,452

)

 

 

(1,985

)

Total Allscripts Healthcare Solutions, Inc.'s stockholders' equity

 

 

1,087,475

 

 

 

1,120,882

 

Non-controlling interest

 

 

29,204

 

 

 

39,190

 

Total stockholders’ equity

 

 

1,116,679

 

 

 

1,160,072

 

Total liabilities and stockholders’ equity

 

$

4,518,080

 

 

$

4,230,150

 

 

The accompanying notes are an integral part of these consolidated financial statements.

4


ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

 

 

Three Months Ended

September 30,

 

 

Nine Months Ended

September 30,

 

(In thousands, except per share amounts)

 

2018

 

 

2017

 

 

2018

 

 

2017

 

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Software delivery, support and maintenance

 

$

330,397

 

 

$

289,102

 

 

$

996,569

 

 

$

832,323

 

Client services

 

 

191,882

 

 

 

160,340

 

 

 

565,213

 

 

 

456,685

 

Total revenue

 

 

522,279

 

 

 

449,442

 

 

 

1,561,782

 

 

 

1,289,008

 

Cost of revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Software delivery, support and maintenance

 

 

109,682

 

 

 

86,893

 

 

 

328,534

 

 

 

259,361

 

Client services

 

 

159,669

 

 

 

132,629

 

 

 

480,231

 

 

 

379,797

 

Amortization of software development and acquisition-related assets

 

 

34,557

 

 

 

28,001

 

 

 

101,008

 

 

 

81,788

 

Total cost of revenue

 

 

303,908

 

 

 

247,523

 

 

 

909,773

 

 

 

720,946

 

    Gross profit

 

 

218,371

 

 

 

201,919

 

 

 

652,009

 

 

 

568,062

 

Selling, general and administrative expenses

 

 

133,214

 

 

 

117,352

 

 

 

425,365

 

 

 

340,234

 

Research and development

 

 

69,747

 

 

 

51,057

 

 

 

220,066

 

 

 

146,748

 

Asset impairment charges

 

 

0

 

 

 

0

 

 

 

30,075

 

 

 

0

 

Amortization of intangible and acquisition-related assets

 

 

13,000

 

 

 

8,137

 

 

 

37,210

 

 

 

23,340

 

Income (loss) from operations

 

 

2,410

 

 

 

25,373

 

 

 

(60,707

)

 

 

57,740

 

Interest expense

 

 

(29,343

)

 

 

(22,252

)

 

 

(80,843

)

 

 

(62,722

)

Other loss, net

 

 

(525

)

 

 

(570

)

 

 

(590

)

 

 

(545

)

Gain on sale of businesses, net

 

 

0

 

 

 

0

 

 

 

172,258

 

 

 

0

 

Impairment of long-term investments

 

 

0

 

 

 

(20,700

)

 

 

(15,487

)

 

 

(165,290

)

Equity in net (loss) income of unconsolidated investments

 

 

(177

)

 

 

449

 

 

 

529

 

 

 

706

 

(Loss) income from continuing operations before income taxes

 

 

(27,635

)

 

 

(17,700

)

 

 

15,160

 

 

 

(170,111

)

Income tax benefit

 

 

3,789

 

 

 

238

 

 

 

3,020

 

 

 

1,073

 

(Loss) income from continuing operations, net of tax

 

 

(23,846

)

 

 

(17,462

)

 

 

18,180

 

 

 

(169,038

)

Income from discontinued operations, net of tax

 

 

0

 

 

 

0

 

 

 

3,731

 

 

 

0

 

Net (loss) income

 

 

(23,846

)

 

 

(17,462

)

 

 

21,911

 

 

 

(169,038

)

Less: Net loss (income) attributable to non-controlling interests

 

 

4

 

 

 

(163

)

 

 

3,494

 

 

 

(352

)

Less: Accretion of redemption preference on redeemable

   convertible non-controlling interest - Netsmart

 

 

(12,149

)

 

 

(10,962

)

 

 

(36,446

)

 

 

(32,887

)

Net loss attributable to Allscripts Healthcare

   Solutions, Inc. stockholders

 

$

(35,991

)

 

$

(28,587

)

 

$

(11,041

)

 

$

(202,277

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss attributable to Allscripts Healthcare

   Solutions, Inc. stockholders per share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Continuing operations

 

$

(0.20

)

 

$

(0.16

)

 

$

(0.09

)

 

$

(1.12

)

Discontinued operations

 

 

0.00

 

 

 

0.00

 

 

 

0.03

 

 

 

0.00

 

Net loss attributable to Allscripts Healthcare

   Solutions, Inc. stockholders per share

 

$

(0.20

)

 

$

(0.16

)

 

$

(0.06

)

 

$

(1.12

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Continuing operations

 

$

(0.20

)

 

$

(0.16

)

 

$

(0.09

)

 

$

(1.12

)

Discontinued operations

 

 

0.00

 

 

 

0.00

 

 

 

0.03

 

 

 

0.00

 

Net loss attributable to Allscripts Healthcare

   Solutions, Inc. stockholders per share

 

$

(0.20

)

 

$

(0.16

)

 

$

(0.06

)

 

$

(1.12

)

 

The accompanying notes are an integral part of these consolidated financial statements.

5


ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(Unaudited)

 

 

 

 

Three Months Ended

September 30,

 

 

Nine Months Ended

September 30,

 

(In thousands)

 

2018

 

 

2017

 

 

2018

 

 

2017

 

Net (loss) income

 

$

(23,846

)

 

$

(17,462

)

 

$

21,911

 

 

$

(169,038

)

Other comprehensive (loss) income:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Foreign currency translation adjustments

 

 

(60

)

 

 

693

 

 

 

(1,622

)

 

 

3,040

 

Change in unrealized (loss) gain on available for sale securities

 

 

0

 

 

 

(4

)

 

 

0

 

 

 

56,507

 

Change in fair value of derivatives qualifying as cash flow hedges

 

 

(1,602

)

 

 

(692

)

 

 

(2,695

)

 

 

341

 

Other comprehensive (loss) income before income

    tax benefit (expense)

 

 

(1,662

)

 

 

(3

)

 

 

(4,317

)

 

 

59,888

 

Income tax benefit (expense) related to items in

    other comprehensive income (loss)

 

 

416

 

 

 

271

 

 

 

850

 

 

 

(126

)

Total other comprehensive (loss) income

 

 

(1,246

)

 

 

268

 

 

 

(3,467

)

 

 

59,762

 

Comprehensive (loss) income

 

 

(25,092

)

 

 

(17,194

)

 

 

18,444

 

 

 

(109,276

)

Less: Comprehensive loss (income) attributable to

   non-controlling interests

 

 

4

 

 

 

(163

)

 

 

3,494

 

 

 

(352

)

Comprehensive (loss) income, net

 

$

(25,088

)

 

$

(17,357

)

 

$

21,938

 

 

$

(109,628

)

 

The accompanying notes are an integral part of these consolidated financial statements.

6


ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

 

 

Nine Months Ended September 30,

 

(In thousands)

 

2018

 

 

2017

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

Net income (loss)

 

$

21,911

 

 

$

(169,038

)

Adjustments to reconcile net loss to net cash provided by operating

   activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

200,829

 

 

 

155,108

 

Stock-based compensation expense

 

 

29,810

 

 

 

28,140

 

Excess tax benefits from stock-based compensation

 

 

0

 

 

 

0

 

Write-off of unamortized deferred debt issuance costs - Netsmart

 

 

855

 

 

 

0

 

Deferred taxes

 

 

(5,347

)

 

 

(5,324

)

Asset impairment charges

 

 

30,075

 

 

 

0

 

Impairment of long-term investments

 

 

15,487

 

 

 

165,290

 

Equity in net income of unconsolidated investments

 

 

(529

)

 

 

(706

)

Gain on sale of businesses, net

 

 

(172,258

)

 

 

0

 

Other (losses) income, net

 

 

(101

)

 

 

3,711

 

Changes in operating assets and liabilities (net of businesses acquired):

 

 

 

 

 

 

 

 

Accounts receivable and contract assets, net

 

 

8,051

 

 

 

(31,256

)

Prepaid expenses and other assets

 

 

(8,901

)

 

 

(6,939

)

Accounts payable

 

 

19,111

 

 

 

2,908

 

Accrued expenses

 

 

8,817

 

 

 

(6,196

)

Accrued compensation and benefits

 

 

(4,873

)

 

 

5,930

 

Deferred revenue

 

 

(59,595

)

 

 

18,661

 

Other liabilities

 

 

(1,788

)

 

 

12,894

 

   Net cash provided by operating activities

 

 

81,554

 

 

 

173,183

 

Cash flows from investing activities:

 

 

 

 

 

 

 

 

Capital expenditures

 

 

(26,670

)

 

 

(40,216

)

Capitalized software

 

 

(101,272

)

 

 

(107,079

)

Cash paid for business acquisitions, net of cash acquired

 

 

(343,873

)

 

 

(54,308

)

Cash received from sale of businesses, net

 

 

241,153

 

 

 

0

 

Purchases of equity securities, other investments and related

   intangible assets

 

 

(2,723

)

 

 

(5,423

)

Other proceeds from investing activities

 

 

64

 

 

 

215

 

   Net cash used in investing activities

 

 

(233,321

)

 

 

(206,811

)

Cash flows from financing activities:

 

 

 

 

 

 

 

 

Proceeds from sale or issuance of common stock

 

 

1,283

 

 

 

0

 

Taxes paid related to net share settlement of equity awards

 

 

(8,763

)

 

 

(6,777

)

Payments of capital lease obligations

 

 

(8,071

)

 

 

(9,013

)

Credit facility payments

 

 

(260,478

)

 

 

(115,281

)

Credit facility borrowings, net of issuance costs

 

 

497,493

 

 

 

189,698

 

Repurchase of common stock

 

 

(101,905

)

 

 

(12,077

)

Payment of acquisition financing obligations

 

 

(3,226

)

 

 

(2,398

)

(Purchases) sales of subsidiary shares owned by non-controlling interest

 

 

(6,945

)

 

 

1,494

 

   Net cash provided by financing activities

 

 

109,388

 

 

 

45,646

 

Effect of exchange rate changes on cash and cash equivalents

 

 

(328

)

 

 

796

 

Net (decrease) increase in cash and cash equivalents

 

 

(42,707

)

 

 

12,814

 

Cash, cash equivalents and restricted cash, beginning of period

 

 

162,498

 

 

 

96,610

 

Cash, cash equivalents and restricted cash, end of period

 

$

119,791

 

 

$

109,424

 

The accompanying notes are an integral part of these consolidated financial statements.


7


ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

 

1. Basis of Presentation and Significant Accounting Policies

Principles of Consolidation

The consolidated financial statements include the accounts of Allscripts Healthcare Solutions, Inc. (“Allscripts”) and its wholly-owned subsidiaries and controlled affiliates. All significant intercompany balances and transactions have been eliminated. Each of the terms “we,” “us,” “our” or the “Company” as used herein refers collectively to Allscripts Healthcare Solutions, Inc. and its wholly-owned subsidiaries and controlled affiliates, unless otherwise stated.

Unaudited Interim Financial Information

The unaudited interim consolidated financial statements as of and for the three and nine months ended September 30, 2018 and 2017 have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. These interim consolidated financial statements are unaudited and, in the opinion of our management, include all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the consolidated financial statements for the periods presented in accordance with generally accepted accounting principles in the United States of America (“GAAP”). The consolidated results of operations for the three and nine months ended September 30, 2018 are not necessarily indicative of the results to be expected for the full year ending December 31, 2018.

Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with the SEC's rules and regulations for interim reporting. The Company believes that the disclosures made are adequate to make that information not misleading. These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2017 (our “Form 10-K”).

Use of Estimates

The preparation of consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and the accompanying notes. Actual results could differ materially from these estimates.

Change in Presentation

During the first quarter of 2018, we changed the presentation of certain bundled revenue streams.  Such revenue was previously included as part of software delivery, support and maintenance revenue.  Under the new presentation, such revenue is included as part of client services revenue.  The revenues previously reported for the three and nine months ended September 30, 2017 have been recast to match the new presentation by reducing software delivery, support and maintenance and increasing client services by $5.1 million and $13.6 million, respectively.

Significant Accounting Policies

We adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers: Topic 606 (“ASC 606”) effective on January 1, 2018 using the modified retrospective method for all contracts not completed as of the date of adoption. There have been no other significant changes to our significant accounting policies from those disclosed in our Form 10-K.

Recently Adopted Accounting Pronouncements

In January 2016, the FASB issued Accounting Standards Update No. 2016-01, “Recognition and Measurement of Financial Assets and Financial Liabilities” (“ASU 2016-01”). The amendments in ASU 2016-01 modify the requirements related to the measurement of certain financial instruments in the statement of financial condition and results of operation. Equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) are required to be measured at fair value with changes in fair value recognized in net income. An entity may continue to elect to measure equity investments which do not have a readily determinable fair value at cost with adjustments for impairment, if any, and observable changes in price. In addition, for a liability (other than a derivative liability) that an entity measures at fair value, any change in fair value related to the instrument-specific credit risk (i.e., the entity’s own credit risk), should be presented separately in other comprehensive income and not as a component of net income. ASU 2016-01 also clarifies that an entity should evaluate the need for a valuation allowance on a deferred tax asset related to available-for sale securities in combination with the entity’s other deferred tax assets. We adopted ASU 2016-01 effective January 1, 2018 and there was no immediate impact upon adoption. Refer to Note 4, “Fair Value Measurements and Long-term Investments,” for additional information regarding our unconsolidated equity investments.

8


In January 2017, the FASB issued Accounting Standards Update No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business (“ASU 2017-01”). ASU 2017-01 provides new accounting guidance to assist an entity in evaluating when a set of transferred assets and activities is a business. We adopted ASU 2017-01 effective January 1, 2018 and there was no immediate impact upon adoption.

Accounting Pronouncements Not Yet Adopted

In August 2018, the FASB issued Accounting Standards Update No. 2018-15, “Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40)” (“ASU 2018-15”), which discusses customer accounting for implementation costs incurred in a cloud computing arrangement that is a service contract. ASU 2018-15 requires an entity (customer) in a hosting arrangement that is a service contract to follow the guidance in Subtopic 350-40 to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. Training costs and certain data conversion costs that cannot be capitalized under Subtopic 350-40 also cannot be capitalized for a hosting arrangement that is a service contract. Costs for implementation activities in the application development state are capitalized depending on the nature of the costs, while costs incurred during preliminary stages are expensed. ASU 2018-15 requires the entity to expense the capitalized implementation costs of a hosting arrangement that is a service contract over the term of the hosting arrangement and apply existing impairment guidance in Subtopic 350-40 to the capitalized implementation costs related to each module or component of a hosting arrangement that is a service contract. ASU 2018-15 also requires the entity to present the expense related to the capitalized implementation costs in the same line item in the statement of operations as the fees associated with the hosting element of the arrangement and classify payments for capitalized implementation costs in the statement of cash flows in the same manner as payments made for fees associated with the hosting element.  The entity is required to present the capitalized implementation costs in the balance sheet in the same line item that a prepayment for the hosting arrangement fees would be presented. ASU 2018-15 is effective for interim and annual periods beginning after December 15, 2019. Early adoption is permitted and can be applied either retrospectively or prospectively. We early adopted ASU 2018-15 on a prospective basis effective October 1, 2018 and do not expect any impact upon adoption.

In August 2018, the FASB issued Accounting Standards Update No. 2018-13, “Fair Value Measurement (Topic 820) – Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement” (“ASU 2018-13”), which eliminates, adds and modifies certain disclosure requirements for fair value measurements. Entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, but public companies will be required to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value instruments. ASU 2018-13 will be effective for all entities for interim and annual periods beginning after December 15, 2019, with early adoption permitted. We are currently evaluating the impact of this accounting guidance.

In June 2018, the FASB issued Accounting Standards Update No. 2018-07, “Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting” (“ASU 2018-07”), which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. ASU 2018-07 specifies that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in its own operations by issuing share-based payment awards. ASU 2018-07 also clarifies that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under ASC 606. ASU 2018-07 is effective for interim and annual periods beginning after December 15, 2018. We are currently evaluating the impact of this accounting guidance.

In February 2016, the FASB issued Accounting Standards Update No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”), intended to improve financial reporting about leasing transactions. The new guidance will require entities that lease assets to recognize on their balance sheets the assets and liabilities for the rights and obligations created by those leases and to disclose key information about the leasing arrangements. ASU 2016-02 is effective for interim and annual periods beginning after December 15, 2018 with early adoption permitted. We plan to adopt ASU 2016-02 on January 1, 2019 using the cumulative-effect adjustment transition method approved by the FASB in July 2018. We are in the process of implementing changes to our processes and internal controls to meet the new reporting and disclosure requirements. We have implemented a software tool to assist us in the calculation of the amount of additional assets and liabilities to be included on our consolidated balance sheet related to leases currently classified as operating leases with durations greater than twelve months. In addition to existing lease agreements, we are also reviewing service contracts and other agreements to determine if they contain an embedded lease. We continue to evaluate the expected impact of ASU 2016-02 on disclosures, but do not anticipate any material changes to operating results or liquidity as a result of right-of-use assets and corresponding lease liabilities that will be recorded.

9


In January 2017, the FASB issued Accounting Standards Update No. 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment (“ASU 2017-04”), which provides new accounting guidance to simplify the accounting for goodwill impairment. ASU 2017-04 removes Step Two of the goodwill impairment test, which requires a hypothetical purchase price allocation. Under the new guidance, a goodwill impairment will equal the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill assigned to the reporting unit. All other goodwill impairment guidance will remain largely unchanged. Entities will continue to have the option to perform a qualitative assessment to determine if a quantitative impairment test is necessary. ASU 2017-04 is effective for annual and interim periods in fiscal years beginning after December 15, 2019 with early adoption permitted for any goodwill impairment tests performed after January 1, 2017. The new guidance is to be applied prospectively. We are currently evaluating the impact of this accounting guidance, including the timing of adoption.

In August 2017, the FASB issued Accounting Standards Update No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities (“ASU 2017-12”), which provides new accounting guidance to simplify and improve the reporting of hedging relationships to better portray the economic results of an entity’s risk management activities in its financial statements. In addition to that main objective, the amendments in ASU 2017-12 make certain targeted improvements to simplify the application of the hedge accounting guidance in current GAAP. ASU 2017-12 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years, with early adoption permitted. We will adopt ASU 2017-02 on January 1, 2019.

We do not believe that any other recently issued, but not yet effective accounting standards, if adopted, would have a material impact on our consolidated financial statements.

 

2. Revenue from Contracts with Customers

Our two primary revenue streams are (i) software delivery, support and maintenance and (ii) client services. Software delivery, support and maintenance revenue consists of all of our proprietary software sales (either under a perpetual or term license delivery model), subscription-based software sales, transaction-related revenue, the resale of hardware and third-party software and revenue from post-contract client support and maintenance services, which include telephone support services, maintaining and upgrading software and ongoing enhanced maintenance. Client services revenue consists of revenue from managed services solutions, such as private cloud hosting, outsourcing and revenue cycle management, as well as other client services and project-based revenue from implementation, training and consulting services. For some clients, we host the software applications licensed from us using our own or third-party servers. For other clients, we offer an outsourced service in which we assume partial to total responsibility for a healthcare organization’s IT operations using our employees.

Adoption of New Revenue Standard (“ASC 606”)

In May 2014, the FASB issued ASC 606 to supersede nearly all existing revenue recognition guidance under GAAP. The core principle of ASC 606 is to recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASC 606 defines a five-step process to achieve this principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under the previous FASB Accounting Standards Codification 605, Revenue Recognition (“ASC 605”), including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation and accounting for significant financing components. Additionally, ASC 606 provides guidance related to costs of obtaining a contract with a customer that an entity expects to recover.

The new revenue recognition guidance permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (modified retrospective method).  We adopted the standard effective on January 1, 2018 using the modified retrospective method. We also implemented internal controls, and continue to refine our updated processes and key systems to allow us to continue to comply with the new requirements.

10


The reported results for the three and nine months ended September 30, 2018 reflect the adoption of ASC 606. The comparative information for the three and nine months ended September 30, 2017 has not been restated and will continue to be reported under the previous guidance of ASC 605, which was in effect during that period. The table below reflects the cumulative adjustments that were made to balances previously reported in the condensed consolidated balance sheet as of December 31, 2017. During the nine months ended September 30, 2018, we identified additional cumulative adjustments, which resulted in a decrease to Accumulated deficit of $14.8 million, an increase to Accounts receivable, net of $0.6 million, an increase to Contract assets of $13.9 million, an increase to Deferred taxes, net of $5.2 million and a decrease to Deferred revenue, current of $5.5 million.  

 

 

As Reported

 

 

Adjustments

 

 

Adjusted

 

(In thousands)

 

December 31, 2017

 

 

due to ASC 606

 

 

January 1, 2018

 

Accounts receivable, net

 

$

567,873

 

 

$

(31,948

)

 

$

535,925

 

Contract assets

 

 

0

 

 

 

90,449

 

 

 

90,449

 

Prepaid expenses and other current assets

 

 

115,463

 

 

 

11,646

 

 

 

127,109

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Deferred revenue, current

 

 

546,830

 

 

 

(12,901

)

 

 

533,929

 

Deferred revenue, long-term

 

 

24,047

 

 

 

0

 

 

 

24,047

 

Deferred taxes, net

 

 

93,643

 

 

 

21,668

 

 

 

115,311

 

Accumulated deficit

 

 

(338,150

)

 

 

61,380

 

 

 

(276,770

)

 

The adoption of ASC 606 had no impact on cash from or used in operating, financing or investing activities reported in our consolidated statement of cash flows for the year ended December 31, 2017. The following tables compare the reported condensed consolidated balance sheet and statement of operations as of and for the three and nine months ended September 30, 2018 to the pro-forma amounts assuming the previous guidance of ASC 605 had been in effect:

 

 

September 30, 2018

 

(In thousands)

 

As reported

under ASC 606

 

 

Adjustments due to ASC 606

 

 

Pro forma

under ASC 605

 

Accounts receivable, net

 

$

520,381

 

 

$

52,523

 

 

$

572,904

 

Contract assets

 

 

71,745

 

 

 

(71,745

)

 

 

0

 

Prepaid expenses and other current assets

 

 

131,826

 

 

 

(13,184

)

 

 

118,642

 

Contract assets - long-term

 

 

52,555

 

 

 

(52,555

)

 

 

0

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Deferred revenue, current

 

 

506,568

 

 

 

21,522

 

 

 

528,090

 

Deferred taxes, net

 

 

124,294

 

 

 

(27,816

)

 

 

96,478

 

Accumulated deficit

 

 

(251,363

)

 

 

(78,667

)

 

 

(330,030

)

 

 

 

 

 

Three Months Ended September 30, 2018

 

(In thousands, except per share amounts)

 

As reported

under ASC 606

 

 

Adjustments due to ASC 606

 

 

Pro forma

under ASC 605

 

Software delivery, support and maintenance

 

$

330,397

 

 

$

(4,351

)

 

$

326,046

 

Client services

 

 

191,882

 

 

 

(5,516

)

 

 

186,366

 

Gross profit

 

 

218,371

 

 

 

(9,119

)

 

 

209,252

 

Selling, general and administrative expenses

 

 

133,214

 

 

 

247

 

 

 

133,461

 

Income (loss) from operations

 

 

2,410

 

 

 

(9,366

)

 

 

(6,956

)

Loss from continuing operations

    before income taxes

 

 

(27,635

)

 

 

(9,598

)

 

 

(37,233

)

Income tax benefit

 

 

3,789

 

 

 

2,522

 

 

 

6,311

 

Net loss

 

 

(23,846

)

 

 

(7,076

)

 

 

(30,922

)

Net loss attributable to Allscripts Healthcare

   Solutions, Inc. stockholders

 

$

(35,991

)

 

$

(7,076

)

 

$

(43,067

)

Loss per share - basic attributable to Allscripts

   Healthcare Solutions, Inc. stockholders

 

$

(0.20

)

 

$

(0.04

)

 

$

(0.24

)

Loss per share - diluted attributable to Allscripts

   Healthcare Solutions, Inc. stockholders

 

$

(0.20

)

 

$

(0.04

)

 

$

(0.24

)

 

11


 

 

Nine Months Ended September 30, 2018

 

(In thousands, except per share amounts)

 

As reported

under ASC 606

 

 

Adjustments due to ASC 606

 

 

Pro forma

under ASC 605

 

Software delivery, support and maintenance

 

$

996,569

 

 

$

(15,486

)

 

$

981,083

 

Client services

 

 

565,213

 

 

 

(7,469

)

 

 

557,744

 

Gross profit

 

 

652,009

 

 

 

(22,539

)

 

 

629,470

 

Selling, general and administrative expenses

 

 

425,365

 

 

 

140

 

 

 

425,505

 

Loss from operations

 

 

(60,707

)

 

 

(22,679

)

 

 

(83,386

)

Income (loss) from continuing operations

    before income taxes

 

 

15,160

 

 

 

(23,435

)

 

 

(8,275

)

Income tax (provision) benefit

 

 

3,020

 

 

 

6,148

 

 

 

9,168

 

Net income

 

 

21,911

 

 

 

(17,287

)

 

 

4,624

 

Net loss attributable to Allscripts Healthcare

   Solutions, Inc. stockholders

 

$

(11,041

)

 

$

(17,287

)

 

$

(28,328

)

Loss per share - basic attributable to Allscripts

   Healthcare Solutions, Inc. stockholders

 

$

(0.06

)

 

$

(0.10

)

 

$

(0.16

)

Loss per share - diluted attributable to Allscripts

   Healthcare Solutions, Inc. stockholders

 

$

(0.06

)

 

$

(0.10

)

 

$

(0.16

)

 

The recognition of revenue related to hardware sales, software-as-a-service-based offerings, client services, electronic data interchange services and managed services remained substantially unchanged under ASC 606. The adoption of ASC 606 resulted in an increase in contract assets driven by upfront recognition of revenue, rather than over the subscription period, from certain multi-year software subscription contracts that include both software licenses and software support and maintenance.

Costs to Obtain or Fulfill a Contract

Under ASC 605, we only capitalized direct sales commissions that were specifically associated with new or renewal contracts. The new revenue recognition guidance under ASC 606 requires the capitalization of all incremental costs of obtaining a contract with a customer that an entity expects to recover. As part of our implementation efforts, we identified certain indirect commissions and other payments that were eligible for capitalization under ASC 606 as they were incremental costs solely associated with new or renewal contracts that we expected to recover. Certain costs related to the fulfillment of contracts are also capitalized. As a result, we recorded a deferral for such costs of $8.6 million, net of tax, upon adoption of the new guidance on January 1, 2018, which was included in the cumulative effect of initially applying ASC 606.

Capitalized costs to obtain or fulfill a contract are amortized over periods ranging from two to nine years which represent the initial contract term or a longer period, if renewals are expected and the renewal commission, if any, is not commensurate with the initial commission. We classify such capitalized costs as current or non-current based on the expected timing of expense recognition. The current and non-current portions are included in Prepaid expenses and other current assets, and Other assets, respectively, in our consolidated balance sheets.

At September 30, 2018, we had capitalized costs to obtain or fulfill a contract of $26.6 million in Prepaid and other current assets and $34.2 million in Other assets. During the three months ended September 30, 2018, we recognized $7.5 million of amortization expense related to such capitalized costs, of which $7.4 million is included in selling, general and administrative expenses and $0.1 million is included in cost of revenue in our consolidated statements of operations. During the nine months ended September 30, 2018, we recognized $23.3 million of amortization expense related to such capitalized costs, of which $22.9 million is included in selling, general and administrative expenses and $0.4 million is included in cost of revenue in our consolidated statement of operations.

Contract Balances

The timing of revenue recognition, billings and cash collections results in billed and unbilled accounts receivables, contract assets and customer advances and deposits. Accounts receivable, net includes both billed and unbilled amounts where the right to receive payment is unconditional and only subject to the passage of time. Contract assets include amounts where revenue recognized exceeds the amount billed to the customer and the right to payment is not solely subject to the passage of time. Deferred revenue includes advanced payments and billings in excess of revenue recognized. Our contract assets and deferred revenue are reported in a net position on an individual contract basis at the end of each reporting period. Contract assets are classified as current or long-term based on the timing of when we expect to complete the related performance obligations and bill the customer. Deferred revenue is classified as current or long-term based on the timing of when we expect to recognize revenue.

12


In general, with the exception of fixed fee project-based client service offerings (such as implementation services), we sell our software solutions on date-based milestone events where control transfers and use of the software occurs on the delivery date but the associated payments for the software license occur on future milestone dates. In such instances, unbilled amounts are included in contract assets since our right to receive payment is conditional upon the continued functionality of the software and the provision of ongoing support and maintenance. Our fixed fee project-based client service offerings typically require us to provide the services with either a significant portion or all amounts due prior to service completion. Since our right to payment is not unconditional, amounts associated with work prior to the completion date are also deemed to be contract assets.

Performance Obligations

A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of account in ASC 606. A performance obligation is considered distinct when both (i) a customer can benefit from the product or service either on its own or together with other resources that are readily available to the customer and (ii) the promised product or service is separately identifiable from other promises in the contract. Activities related to the fulfillment of a contract that do not transfer products or services to a customer, such as contract preparation or legal review of contract terms, are not deemed to be performance obligations. Based on the similarities in the definitions of a “deliverable” under ASC 605 and “performance obligation” under ASC 606, our identification of performance obligations under ASC 606 did not result in a significant divergence from our existing identification approach.

We generally sell our solutions through multi-element arrangements where we provide the customer with (1) software license, (2) support and maintenance, (3) embedded content such as third-party software and (4) client services.  Incremental solutions, such as hardware and managed services are also provided based upon a customer’s preferences and requirements. We deem that a customer is typically able to benefit from a product or service on its own or together with readily available resources when we sell such product or service on a standalone basis.  We have historically sold the majority of our performance obligations, with the exception of software licenses, on a standalone basis.  Incremental solutions, such as hardware, client services and managed services, are often negotiated and fulfilled on an independent sales order basis as customer needs and requirements change over the course of a relationship period.  In addition, support and maintenance and embedded content are provided on a stand-alone basis through the renewal process.

One of the product offerings under our CareInMotionTM platform requires significant client service customization to enable the functionality of the software before the customer can obtain benefit from using the product. The significant customization cannot be performed by a third party. Software products and client services are separately identifiable in these contracts, but the performance obligations are not considered distinct in the context of the contract. Therefore, these products and services are treated as a combined performance obligation.  

Additionally, our support and maintenance obligations include multiple discrete performance obligations, with the two largest being unspecified product upgrades or enhancements, and technical support, which can be offered at various points during a contract period. We believe that the multiple discrete performance obligations within our overall support and maintenance obligations can be viewed as a single performance obligation since both the unspecified product upgrades and technical support are activities to fulfill the maintenance performance obligation and are rendered concurrently.

The breakdown of revenue recognized related based on the origination of performance obligations and elected accounting expedients is presented in the table below:

 

(In thousands)

 

Three Months Ended

March 31, 2018

 

 

Three Months Ended

June 30, 2018

 

 

Three Months Ended

September 30, 2018

 

Revenue related to deferred revenue balance at beginning of period

 

$

204,297

 

 

$

215,519

 

 

$

177,692

 

Revenue related to new performance obligations satisfied

   during the period

 

 

257,222

 

 

 

244,082

 

 

 

290,145

 

Revenue recognized under "right-to-invoice" expedient

 

 

49,638

 

 

 

62,812

 

 

 

51,587

 

Reimbursed travel expenses, shipping and other revenue

 

 

2,769

 

 

 

3,164

 

 

 

2,855

 

Total revenue

 

$

513,926

 

 

$

525,577

 

 

$

522,279

 

 

           The aggregate amount of contract transaction price related to remaining unsatisfied performance obligations (commonly referred to as “backlog”) represents contracted revenue that has not yet been recognized and includes both deferred revenue and amounts that will be invoiced and recognized as revenue in future periods. Total backlog equaled $4.7 billion as of September 30, 2018, of which we expect to recognize approximately 39% over the next 12 months, and the remaining 61% thereafter.

Transaction price and allocation

Our contracts with customers often include multiple distinct performance obligations such as software licenses, software support and maintenance, hardware, client services, private cloud hosting and Software-as-a-Service. We adjust the transaction price on a contract-by-contract basis for (i) the effect of the time value of money when a contract has a significant financing component and/or (ii) customer discounts and incentives deemed to be variable consideration. We then allocate the contract transaction price to

13


the distinct performance obligations in the contract. Such allocation is based on the stand-alone selling price (“SSP”) of each distinct performance obligation. The transaction price allocated to each distinct performance obligation is adjusted for discounts offered to customers that are outside of the Company’s established sufficiently narrow ranges for distinct performance obligations’ SSPs on a relative SSP basis.

For each distinct performance obligation, we use observable stand-alone pricing to determine the SSP. Such observable SSPs are based upon our listed sales prices and consider discounts offered to customers. In instances where SSP is not directly observable because we do not sell the product or service separately, we determine the SSP through the residual approach or cost-plus margin models using information that includes market conditions and other observable inputs. Such instances primarily relate to sales of new products and service offerings and our acute suite of software licenses. Our acute suite of software licenses is sold to a diverse set of customers for a broad range of amounts and, therefore, SSP is not discernible from past transactions due to the high variability of selling prices.

Our products and services are generally not sold with a right of return, except for certain hardware sales, which are not material to our consolidated revenue. We may provide credits or incentives on a contract-by-contract basis which are accounted for either as a material right or as variable consideration, respectively, when allocating the transaction price. Such credits and incentives have historically not been significant.  We do not provide additional warranties to clients above and beyond warranties that the solutions purchased will perform in accordance with the agreed-upon specifications. On rare occasions, when additional warranties are granted, we evaluate on a case-by-case basis whether the additional warranty granted represents a separate performance obligation.

The majority of our contracts contain provisions that require customer payment no later than one year from the transfer of control of the related performance obligation. Some of our contracts contain a significant financing component resulting in a time value of money adjustment when the distinct performance obligation, such as software licenses, is delivered at a point in time, but the customer payments are over an extended future period that can range from 2 to 10 years. The time value of money adjustment is excluded from the transaction price at contract inception and is recognized over the respective future payment term as interest income. The discount rate used is determined at the time of contract inception and is based on investment grade bond rates with duration equal to the expected payment term. Interest income recognized totaled $0.2 million and $0.7 million during the three and nine months ended September 30, 2018, respectively.

 

Accounting Policy Elections and Practical Expedients

We have elected to exclude from the measurement of the transaction price all taxes (e.g., sales, use, value-added) assessed by government authorities and collected from a customer. Therefore, revenue is recognized net of such taxes.

Within the normal course of business, we contract with customers to deliver and ship tangible products, such as computer hardware. In these situations, the control of the products transfers to the customer when the product reaches the shipper based on free on board (FOB) shipping clauses. We have elected to use the practical expedient allowed under ASC 606 to account for shipping and handling activities that occur after the customer has obtained control of a promised good as fulfillment costs rather than as an additional promised service and, therefore, we do not allocate a portion of the transaction price to a shipping service obligation. Instead, we record as revenue any amounts billed to customers for shipping and handling costs and record as cost of revenue the actual shipping costs incurred.

Additionally, our standard contract terms allow for the reimbursement by a customer for certain travel expenses necessary to provide on-site services to the customer, such as implementation and training. Such reimbursed travel expenses are reported on a gross basis. Since such reimbursed travel expenses do not represent a distinct good or service nor incremental value provided to a customer, a performance obligation is deemed not to exist. In certain situations, however, when the allowable reimbursable expenses amount is capped, we believe that such cap represents the most likely amount of variable consideration and the capped amount is included in the total contract transaction price.

In accordance with ASC 606, if an entity has a right to consideration from a customer in an amount that corresponds directly with the value to the customer of the entity’s performance completed to date, the entity may recognize revenue in the amount to which the entity has a right to invoice (“right-to-invoice” practical expedient). We have elected to utilize this expedient as it relates to transaction-based services (such as revenue cycle management) and electronic data interchange transactions.

14


Revenue Recognition

We recognize revenue only when we satisfy an identified performance obligation (or bundle of obligations) by transferring control of a promised product or service to a customer. We consider a product or service to be transferred when a customer obtains control because a customer has sole possession of the right to use (or the right to direct the use of) the product or service for the remainder of its economic life or to consume the product or service in its own operations. We evaluate the transfer of control primarily from the customer’s perspective as this reduces the risk that revenue is recognized for activities that do not transfer control to the customer.

The majority of our revenue is recognized over time because a customer continuously and simultaneously rec